Value Set ongoing_immunosuppressive

1.2.276.0.76.11.674

Effective Date

2022‑02‑10 12:35:35

Status

Draft

Version Label

Name

ongoing_immunosuppressive_therapy

Display Name

Immunosuppressive therapy 1 ATC

Source Code System

2.16.840.1.113883.6.73 - WHO Anatomical Therapeutic Chemical classification - FHIR: http://www.whocc.no/atc - HL7 V2: WC

Level/ Type	Code	Display Name	Code System
0‑L	L04AA24	abatacept	WHO Anatomical Therapeutic Chemical classification
0‑L	L04AB04	adalimumab	WHO Anatomical Therapeutic Chemical classification
0‑L	L04AC03	anakinra	WHO Anatomical Therapeutic Chemical classification
0‑L	L04AA32	apremilast	WHO Anatomical Therapeutic Chemical classification
0‑L	L04AX01	azathioprine	WHO Anatomical Therapeutic Chemical classification
0‑L	L04AA37	baricitinib	WHO Anatomical Therapeutic Chemical classification
0‑L	R03DX10	benralizumab	WHO Anatomical Therapeutic Chemical classification
0‑L	L04AC12	brodalumab	WHO Anatomical Therapeutic Chemical classification
0‑L	L04AB05	certolizumab pegol	WHO Anatomical Therapeutic Chemical classification
0‑L	P01BA01	chloroquine	WHO Anatomical Therapeutic Chemical classification
0‑L	L04AD01	ciclosporin	WHO Anatomical Therapeutic Chemical classification
0‑L	L01AA01	cyclophosphamide	WHO Anatomical Therapeutic Chemical classification
0‑L	D11AH05	dupilumab	WHO Anatomical Therapeutic Chemical classification
0‑L	L04AB01	etanercept	WHO Anatomical Therapeutic Chemical classification
0‑L	L04AB06	golimumab	WHO Anatomical Therapeutic Chemical classification
0‑L	L04AC16	guselkumab	WHO Anatomical Therapeutic Chemical classification
0‑L	P01BA02	hydroxychloroquine	WHO Anatomical Therapeutic Chemical classification
0‑L	L04AB02	infliximab	WHO Anatomical Therapeutic Chemical classification
0‑L	L04AC13	ixekizumab	WHO Anatomical Therapeutic Chemical classification
0‑L	L04AA13	leflunomide	WHO Anatomical Therapeutic Chemical classification
0‑L	R03DX09	mepolizumab	WHO Anatomical Therapeutic Chemical classification
0‑L	L01BA01	methotrexate	WHO Anatomical Therapeutic Chemical classification
0‑L	L04AA06	mycophenolic acid	WHO Anatomical Therapeutic Chemical classification
0‑L	L04AA23	natalizumab	WHO Anatomical Therapeutic Chemical classification
0‑L	L04AA36	ocrelizumab	WHO Anatomical Therapeutic Chemical classification
0‑L	R03DX05	omalizumab	WHO Anatomical Therapeutic Chemical classification
0‑L	L01FA01	rituximab	WHO Anatomical Therapeutic Chemical classification
0‑L	L04AC18	risankizumab	WHO Anatomical Therapeutic Chemical classification
0‑L	L04AC14	sarilumab	WHO Anatomical Therapeutic Chemical classification
0‑L	L04AC10	secukinumab	WHO Anatomical Therapeutic Chemical classification
0‑L	D11AH01	tacrolimus	WHO Anatomical Therapeutic Chemical classification
0‑L	L04AC07	tocilizumab	WHO Anatomical Therapeutic Chemical classification
0‑L	L04AA29	tofacitinib	WHO Anatomical Therapeutic Chemical classification
0‑L	L04AC05	ustekinumab	WHO Anatomical Therapeutic Chemical classification
0‑L	L04AA33	vedolizumab	WHO Anatomical Therapeutic Chemical classification

Legenda: Type L=leaf, S=specializable, A=abstract, D=deprecated. NullFlavor OTH (other) suggests text in originalText. HL7 V3: NullFlavors to appear in @nullFlavor attribute instead of @code.

XML JSON CSV SQL SVS